Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Edgewise Therapeutics stock | $16.7

Learn how to easily invest in Edgewise Therapeutics stock.

Edgewise Therapeutics Inc is a biotechnology business based in the US. Edgewise Therapeutics shares (EWTX) are listed on the NASDAQ and all prices are listed in US Dollars. Edgewise Therapeutics employs 26 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Edgewise Therapeutics

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – EWTX – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Edgewise Therapeutics stock price (NASDAQ: EWTX)

Use our graph to track the performance of EWTX stocks over time.

Edgewise Therapeutics shares at a glance

Information last updated 2021-10-23.
Latest market close$16.70
52-week range$13.60 - $40.49
50-day moving average $17.36
200-day moving average $21.93
Wall St. target price$31.75
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-2.05

Buy Edgewise Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
$20 per year
Financial advice powered by relationships, not commissions.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Edgewise Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Edgewise Therapeutics price performance over time

Historical closes compared with the close of $16.7 from 2021-10-22

1 week (2021-10-18) -3.86%
1 month (2021-09-24) -8.19%
3 months (2021-07-26) -17.29%
6 months (2021-04-26) -37.80%
1 year (2020-10-22) N/A
2 years (2019-10-22) N/A
3 years (2018-10-22) N/A
5 years (2016-10-22) N/A

Edgewise Therapeutics financials

Gross profit TTM $0
Return on assets TTM -13.8%
Return on equity TTM -22.8%
Profit margin 0%
Book value $6.02
Market capitalisation $822.7 million

TTM: trailing 12 months

Shorting Edgewise Therapeutics shares

There are currently 1.6 million Edgewise Therapeutics shares held short by investors – that's known as Edgewise Therapeutics's "short interest". This figure is 0.8% down from 1.6 million last month.

There are a few different ways that this level of interest in shorting Edgewise Therapeutics shares can be evaluated.

Edgewise Therapeutics's "short interest ratio" (SIR)

Edgewise Therapeutics's "short interest ratio" (SIR) is the quantity of Edgewise Therapeutics shares currently shorted divided by the average quantity of Edgewise Therapeutics shares traded daily (recently around 70513.273942094). Edgewise Therapeutics's SIR currently stands at 22.45. In other words for every 100,000 Edgewise Therapeutics shares traded daily on the market, roughly 22450 shares are currently held short.

To gain some more context, you can compare Edgewise Therapeutics's short interest ratio against those of similar companies.

However Edgewise Therapeutics's short interest can also be evaluated against the total number of Edgewise Therapeutics shares, or, against the total number of tradable Edgewise Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Edgewise Therapeutics's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Edgewise Therapeutics shares in existence, roughly 30 shares are currently held short) or 0.0812% of the tradable shares (for every 100,000 tradable Edgewise Therapeutics shares, roughly 81 shares are currently held short).

A SIR above 20% would generally be considered very high, pointing to a pessimistic outlook for the share price, with a discouraging number of investors currently willing to bet against Edgewise Therapeutics.

Find out more about how you can short Edgewise Therapeutics stock.

Edgewise Therapeutics share dividends

We're not expecting Edgewise Therapeutics to pay a dividend over the next 12 months.

Edgewise Therapeutics overview

Edgewise Therapeutics, Inc. , a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. It offers a precision medicine muscle platform that generates programs to address various muscle disorders, such as Duchenne, Becker, and limb girdle muscular dystrophies. The company develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was founded in 2017 and is headquartered in Boulder, Colorado. .

Frequently asked questions

What percentage of Edgewise Therapeutics is owned by insiders or institutions?
Currently 1.101% of Edgewise Therapeutics shares are held by insiders and 103.551% by institutions.
How many people work for Edgewise Therapeutics?
Latest data suggests 26 work at Edgewise Therapeutics.
When does the fiscal year end for Edgewise Therapeutics?
Edgewise Therapeutics's fiscal year ends in December.
Where is Edgewise Therapeutics based?
Edgewise Therapeutics's address is: 3415 Colorado Avenue, Boulder, CO, United States, 80303
What is Edgewise Therapeutics's ISIN number?
Edgewise Therapeutics's international securities identification number is: US28036F1057

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site